Abstract: A topical composition for skin care or administration of a pharmacologically active agent in form of a lotion, cream or similar comprises from 5% to 70% by weight of pentane-1,5-diol and a cosmetically or pharmaceutically acceptable carrier, with the proviso that the composition does not comprise polysiloxane, volatile siloxane, phosphatidyl-choline, creatine, carnitine, panthenol, pyruvic acid, monoglyceride of lauric acid, monoglyceride of myristic acid. Also disclosed are corresponding methods of administration, a patch for holding said composition against the skin, and methods of preventing or treating a dry skin condition and of keeping skin in a humid state.

Abstract: This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.

Abstract: The invention encompasses compositions for enhancing the ability of a companion animal to resist and/or overcome viral infections. The compositions of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal.

Abstract: A food composition comprises an antioxidant component comprising at least one of alpha-lipoic acid and L-carnitine, said composition meeting ordinary nutritional requirements for an adult canine or feline.

Abstract: A hair styling composition comprising: i) an amino acid comprising an urea moiety in its side chain; ii) a solvent for component i).

Abstract: The present invention relates to the use of 4-methyl-delta-hexylactone for imparting, modifying and/or intensifying one or more smell or flavor impressions from the group consisting of hay, coumarin, lactone and richness in the mouth.

Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Abstract: The invention relates to medicine, namely, to stomatology, in particular, to formulation for prophylaxis of oral cavity diseases. The formulation comprises: drinking water, glycerol, xylitol, silica, xanthan gum, methylparaben, propylparaben, titanium dioxide, perfume, bromelain, sodium saccharin, sodium lauryl sulfate or alkylamidobetain, calcium glycerophosphate, and magnesium chloride or glycerophosphate magnesium at following component ratio, % wt.: glycerol—20-25; xylitol—10-14; i 10 silica—22-26; xanthan gum—1.2-1.4; methylparaben—0.2-0.3; propylparaben—0.08-0.12; sodium saccharin—0.1-0.3; titanium dioxide—0.2-0.4; perfume—0.7-1.0; bromelain—0.1-0.7; sodium lauryl sulfate—1.2-1.4 or alkylamidobetain—1.2; calcium glycerophosphate—0.6-1.0; magnesium chloride—0.08-0.16 or magnesium glycerophosphate—0.16; and water—up to 100.

Abstract: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.

Abstract: The invention provides an antiplaque oral composition containing an orally acceptable carrier and an antibacterial effective amount of compound (I): In the structure, R1 and R2 are independently a hydrogen atom or a lower C1-4 alkyl group and R3 and R4 are independently an alkenyl or alkyl group having from 1 to 20 carbon atoms, with the proviso that R3 and R4 are not both 2-propenyl or n-propyl when R1 and R2 are both hydrogen atoms. Also included are oral compositions containing the compound (I).

Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Abstract: Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.

Abstract: The invention relates to a new use of cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, according to the following formula: where: X? is Br?, Cl?, or HSO4?. R1: is linear alkyl chain from a saturated fatty acid, or hydroxyacid from 8 to 14 atoms of carbon bonded to the ?-amino acid group through amidic bond. R2: is a lineal or branched alkyl chain from 1 to 18 carbon atoms or aromatic, and R3: is: and n can be from 0 to 4. This class of compounds turned out to be highly suitable for use as preservatives in cosmetic or dermatological preparations. A particularly suitable compound is the ethyl ester of the lauramide of arginine hydrochloride (LAE).

Abstract: Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation and induced apoptosis of cancer cells, enhanced the sensitivity of different cancer cells to different therapeutic drugs including cisplatin and taxol. Apigenin also inhibits angiogenesis and tumor growth in human cancers, and inhibits angiogenic inducers such as hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF). Apigenin inhibited expression of HIF-1 and VEGF through PI3K, AKT, p70S6K1 and HDM2 pathways, which are commonly observed in all kinds of human cancers.

Abstract: The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium, a high amount of magnesium stearate, and a low level of a hydrophilic polymer such as a methocel, and a method of preparing the same by blending.

Abstract: An object of the present invention is to provide a new insecticidal compound by paying attention to the insecticidal activity contained in the flower part of marigold, and to provide an insecticide containing the compound as an active ingredient. There are provided an insecticidal compound represented by the following chemical formula: [Formula 1], and an insecticide containing the insecticidal compound as an active ingredient or an insecticide containing, as active ingredients, the insecticidal compound and an insecticidal compound represented by the following chemical formula: [Formula 2], wherein the insecticide can exhibit extraordinary insecticidal efficacy compared with existing pyrethroid-based insecticidal compounds.

Abstract: The invention provides an antiplaque oral composition that includes an orally acceptable carrier; and an antibacterially effective amount of a compound of structure (I) In the structure, R1 and R2 are independently selected from a lower C1-4 alkyl group and R3 and R4 are independently an alkenyl or alkyl group having from 1 to 20 carbon atoms. Also included in the invention are toothpastes or tooth gels that include at least one humectant: at least one abrasive compound; and an antibacterially effective amount of the compound represented by the structure of formula (I). Also provided are methods of inhibiting bacterial growth in the oral cavity of an animal by application of the compound of formula (I).

Abstract: The present invention refers to a treatment for mixed infectious diseases in the human reproductive system, wherein an association of compounds containing fluconazole and either tinidazole or secnidazole is used, the same being associated in doses lower to those commonly used therapeutically. The combination has proven to be highly efficacious and shown a good degree of tolerance.